For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal reflux disease (GERD) and its complications compared ...

No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 ...

In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations ...

Learn what Type 1 diabetes is how it differs from other forms of diabetes and what causes it Understand key symptoms early ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.

Innovative stem cell therapy shows promise in restoring insulin production for severe type 1 diabetes patients.